<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560299</url>
  </required_header>
  <id_info>
    <org_study_id>Metiodine</org_study_id>
    <nct_id>NCT01560299</nct_id>
  </id_info>
  <brief_title>Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iodine therapy is the best treatment for graves disease.Most patients receive methimozale
      prior to radio-iodine treatment. This may decrease treatment response to iodine therapy.

      Some physicians advice to discontinue methimazole 3 days before radioiodine therapy and
      others prefer longer off - methimazole period which bothers most patients. This study aimed
      to evaluate optimum time for methimazole discontinuation in graves disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>thyroid function tests over one year after radioiodine therapy</measure>
    <time_frame>months 1 , 3 ,6,9,12</time_frame>
    <description>thyroid function test may change over one year . In order to consider the patients as cured ,thyroid function tests should reveal hypothyroidism or euthyroidism . In order to rule out temporary hypothyroidism the tests should be repeated after 6 months of radioiodine therapy.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Graves Disease</condition>
  <arm_group>
    <arm_group_label>group one</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be advised to discontinue methimazole 24-48 hour before iodine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group two</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>methimazole stopped 48-72 hour before radioiodine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group three</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methimazole</intervention_name>
    <description>Methimazole was stopped 24-48 before radio-iodine therapy</description>
    <arm_group_label>group one</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methimazole</intervention_name>
    <description>methimazole discontinued 49-72 hours before radioiodine treatment</description>
    <arm_group_label>group two</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methimazole</intervention_name>
    <description>methimazole discontinued 73-168 hours before radio-iodine treatment</description>
    <arm_group_label>group three</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-65

          -  graves disease(TSH&lt;0.1 &amp;increased FT4 &amp; positive TSI

          -  one or more bartlena criteria for radio-iodine therapy

          -  24 hour RAIU&gt;25%

          -  euthyroidism after methimazole treatment

        Exclusion Criteria:

          -  pregnancy or lactation

          -  moderate or severe graves ophthalmopathy

          -  CHF or coronary heart disease

          -  palpable thyroid nodule

          -  lithium or amiodarone or lugol or ipodate treatment

          -  recent imaging with contrast agent

          -  very large goiter(more than 150 gram)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>rasoul zakavi, associate professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mashhad University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mashad University of Medical Sciences</name>
      <address>
        <city>Mashad</city>
        <state>Khorasan Razavi</state>
        <zip>91766</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>S.R.ZAKAVI</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>hyperthyroidism</keyword>
  <keyword>radio-iodine</keyword>
  <keyword>I-131</keyword>
  <keyword>methimazole</keyword>
  <keyword>graves disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

